136 related articles for article (PubMed ID: 18219411)
1. Design, synthesis, and biological evaluation of novel alkenylthiophenes as potent and selective CB1 cannabinoid receptor antagonists.
Tai CL; Hung MS; Pawar VD; Tseng SL; Song JS; Hsieh WP; Chiu HH; Wu HC; Hsieh MT; Kuo CW; Hsieh CC; Tsao JP; Chao YS; Shia KS
Org Biomol Chem; 2008 Feb; 6(3):447-50. PubMed ID: 18219411
[TBL] [Abstract][Full Text] [Related]
2. 1,2,3-Triazole derivatives as new cannabinoid CB1 receptor antagonists.
Hou DR; Alam S; Kuan TC; Ramanathan M; Lin TP; Hung MS
Bioorg Med Chem Lett; 2009 Feb; 19(3):1022-5. PubMed ID: 19095444
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 1-(2,4-dichlorophenyl)-4-ethyl-5-(5-(2-(4-(trifluoromethyl)phenyl)ethynyl)thiophen-2-yl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide as a potential peripheral cannabinoid-1 receptor inverse agonist.
Hung MS; Chang CP; Li TC; Yeh TK; Song JS; Lin Y; Wu CH; Kuo PC; Amancha PK; Wong YC; Hsiao WC; Chao YS; Shia KS
ChemMedChem; 2010 Sep; 5(9):1439-43. PubMed ID: 20652930
[No Abstract] [Full Text] [Related]
4. Tricyclic pyrazoles. 3. Synthesis, biological evaluation, and molecular modeling of analogues of the cannabinoid antagonist 8-chloro-1-(2',4'-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide.
Murineddu G; Ruiu S; Loriga G; Manca I; Lazzari P; Reali R; Pani L; Toma L; Pinna GA
J Med Chem; 2005 Nov; 48(23):7351-62. PubMed ID: 16279795
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, cannabinoid receptor affinity, molecular modeling studies and in vivo pharmacological evaluation of new substituted 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides. 2. Effect of the 3-carboxamide substituent on the affinity and selectivity profile.
Silvestri R; Ligresti A; La Regina G; Piscitelli F; Gatti V; Brizzi A; Pasquini S; Lavecchia A; Allarà M; Fantini N; Carai MA; Novellino E; Colombo G; Di Marzo V; Corelli F
Bioorg Med Chem; 2009 Aug; 17(15):5549-64. PubMed ID: 19595596
[TBL] [Abstract][Full Text] [Related]
6. Bioisosteric replacement of the pyrazole 5-aryl moiety of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A). A novel series of alkynylthiophenes as potent and selective cannabinoid-1 receptor antagonists.
Tseng SL; Hung MS; Chang CP; Song JS; Tai CL; Chiu HH; Hsieh WP; Lin Y; Chung WL; Kuo CW; Wu CH; Chu CM; Tung YS; Chao YS; Shia KS
J Med Chem; 2008 Sep; 51(17):5397-412. PubMed ID: 18712856
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of piperazine analogues as CB1 cannabinoid receptor ligands.
Song KS; Lee SH; Chun HJ; Kim JY; Jung ME; Ahn K; Kim SU; Kim J; Lee J
Bioorg Med Chem; 2008 Apr; 16(7):4035-51. PubMed ID: 18243711
[TBL] [Abstract][Full Text] [Related]
8. Bioisosteric replacement of the pyrazole 3-carboxamide moiety of rimonabant. A novel series of oxadiazoles as CB1 cannabinoid receptor antagonists.
Chu CM; Hung MS; Hsieh MT; Kuo CW; Suja TD; Song JS; Chiu HH; Chao YS; Shia KS
Org Biomol Chem; 2008 Sep; 6(18):3399-407. PubMed ID: 18802648
[TBL] [Abstract][Full Text] [Related]
9. 1-Aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamide: an effective scaffold for the design of either CB1 or CB2 receptor ligands.
Piscitelli F; Ligresti A; La Regina G; Gatti V; Brizzi A; Pasquini S; Allarà M; Carai MA; Novellino E; Colombo G; Di Marzo V; Corelli F; Silvestri R
Eur J Med Chem; 2011 Nov; 46(11):5641-53. PubMed ID: 21996466
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and structure-activity relationship of 1,2,4-triazole-containing diarylpyrazolyl carboxamide as CB1 cannabinoid receptor-ligand.
Seo HJ; Kim MJ; Lee SH; Lee SH; Jung ME; Kim MS; Ahn K; Kim J; Lee J
Bioorg Med Chem; 2010 Feb; 18(3):1149-62. PubMed ID: 20045337
[TBL] [Abstract][Full Text] [Related]
11. Discovery of 2-[5-(4-chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-ethyl-1H-pyrazol-3-yl]-1,5,5-trimethyl-1,5-dihydro-imidazol-4-thione (BPR-890) via an active metabolite. A novel, potent and selective cannabinoid-1 receptor inverse agonist with high antiobesity efficacy in DIO mice.
Wu CH; Hung MS; Song JS; Yeh TK; Chou MC; Chu CM; Jan JJ; Hsieh MT; Tseng SL; Chang CP; Hsieh WP; Lin Y; Yeh YN; Chung WL; Kuo CW; Lin CY; Shy HS; Chao YS; Shia KS
J Med Chem; 2009 Jul; 52(14):4496-510. PubMed ID: 19530697
[TBL] [Abstract][Full Text] [Related]
12. Biarylpyrazolyl oxadiazole as potent, selective, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity.
Lee SH; Seo HJ; Lee SH; Jung ME; Park JH; Park HJ; Yoo J; Yun H; Na J; Kang SY; Song KS; Kim MA; Chang CH; Kim J; Lee J
J Med Chem; 2008 Nov; 51(22):7216-33. PubMed ID: 18954042
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists.
Behrenswerth A; Volz N; Toräng J; Hinz S; Bräse S; Müller CE
Bioorg Med Chem; 2009 Apr; 17(7):2842-51. PubMed ID: 19278853
[TBL] [Abstract][Full Text] [Related]
14. 3D-QSAR studies of arylpyrazole antagonists of cannabinoid receptor subtypes CB1 and CB2. A combined NMR and CoMFA approach.
Chen JZ; Han XW; Liu Q; Makriyannis A; Wang J; Xie XQ
J Med Chem; 2006 Jan; 49(2):625-36. PubMed ID: 16420048
[TBL] [Abstract][Full Text] [Related]
15. Oxadiazole-diarylpyrazole 4-carboxamides as cannabinoid CB1 receptor ligands.
Lee SH; Seo HJ; Kim MJ; Kang SY; Song KS; Lee SH; Jung ME; Kim J; Lee J
Bioorg Med Chem Lett; 2009 Apr; 19(7):1899-902. PubMed ID: 19269817
[TBL] [Abstract][Full Text] [Related]
16. Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2.
Brogi S; Corelli F; Di Marzo V; Ligresti A; Mugnaini C; Pasquini S; Tafi A
Eur J Med Chem; 2011 Feb; 46(2):547-55. PubMed ID: 21183257
[TBL] [Abstract][Full Text] [Related]
17. Chemical and biological investigation of cyclopropyl containing diaryl-pyrazole-3-carboxamides as novel and potent cannabinoid type 1 receptor antagonists.
Szabó G; Varga B; Páyer-Lengyel D; Szemzo A; Erdélyi P; Vukics K; Szikra J; Hegyi E; Vastag M; Kiss B; Laszy J; Gyertyán I; Fischer J
J Med Chem; 2009 Jul; 52(14):4329-37. PubMed ID: 19527048
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain.
Diaz P; Xu J; Astruc-Diaz F; Pan HM; Brown DL; Naguib M
J Med Chem; 2008 Aug; 51(16):4932-47. PubMed ID: 18666769
[TBL] [Abstract][Full Text] [Related]
19. Probing the cannabinoid CB1/CB2 receptor subtype selectivity limits of 1,2-diarylimidazole-4-carboxamides by fine-tuning their 5-substitution pattern.
Lange JH; van der Neut MA; Borst AJ; Yildirim M; van Stuivenberg HH; van Vliet BJ; Kruse CG
Bioorg Med Chem Lett; 2010 May; 20(9):2770-5. PubMed ID: 20363132
[TBL] [Abstract][Full Text] [Related]
20. Novel 3,4-diarylpyrazolines as potent cannabinoid CB1 receptor antagonists with lower lipophilicity.
Lange JH; van Stuivenberg HH; Veerman W; Wals HC; Stork B; Coolen HK; McCreary AC; Adolfs TJ; Kruse CG
Bioorg Med Chem Lett; 2005 Nov; 15(21):4794-8. PubMed ID: 16140010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
